Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.
about
Toward an integrated software platform for systems pharmacologyReduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Plasma vs heart tissue concentration in humans - literature data analysis of drugs distribution.Using physiologically based models for clinical translation: predictive modelling, data interpretation or something in-between?Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage PredictionsFrom PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine.Model-based dietary optimization for late-stage, levodopa-treated, Parkinson's disease patients.Physiologically based pharmacokinetic modeling and simulation in pediatric drug developmentPhysiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia TherapyHuman-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic NonlinearitySemiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Pharmacists in Australian general practice: an opportunity for expertise in precision medicineEffect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenA Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to HumansGood Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationApplication of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humansPredictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to HumanQuantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application.Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levelsModels for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Computational modeling of drug response with applications to neuroscience.Systems engineering meets quantitative systems pharmacology: from low-level targets to engaging the host defenses.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Tools for predicting the PK/PD of therapeutic proteins.MUFINS: multi-formalism interaction network simulator.Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Pediatric Development of Bosentan Facilitated by Modeling and Simulation.Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.Microtechnology-Based Multi-Organ Models.A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.
P2860
Q28650510-4A43B511-E69B-4655-B86A-F0CA2D7D208BQ30776360-BE59FEC0-DC8C-4C4F-BCE6-2CB7F74BBF57Q30909481-F549408B-32B1-4DAF-A8BA-A3AE720FE768Q31086222-2F0E4181-0187-47AC-AA88-44446855FCF6Q31138430-D11D5057-3167-46EE-9289-7C15A2280F8FQ33600357-4227C185-4A00-4B99-BFB8-3D3014508471Q33917819-F97AF11A-EC17-4110-8675-A6EF8B6EFBFEQ34658074-BB8C1F39-E8AE-4E03-8896-492242499EAAQ35382898-E2B8B140-2E90-4F7F-A98B-0C7E931EE446Q35532165-12914AC4-7616-4FA7-8AE9-1B46D8EBD385Q35560052-BD0B546B-0E9C-471A-BE52-1309EC510794Q35676044-1B0062DE-0DD9-4BFA-A2C4-47168F8AEC68Q35861714-55B537A3-291F-4497-B41C-96EC6C64DC3EQ36090728-FA1C99F7-ED17-4C8A-8EC0-899E06EF7DF1Q36114697-17EFE23E-46E8-457F-8E7C-A0D9BEF46088Q36322918-F45C8DAA-CD74-4323-959D-2AEEBE65811EQ36445112-74C11C4F-1C37-45F8-8AE8-573B141704DFQ36734132-A2CA0B19-2B69-4F96-9CAD-9F0ADEED884FQ37265701-66D70E6F-FE4A-49A9-99EF-B637C8C999AAQ37283027-2E366B1B-00A1-47D1-8917-F7DDF091A7BEQ37507317-F3387C21-D0E8-4D15-B501-5853A768878BQ37540180-3185F36F-6429-4718-8CA4-FD2BB07409F6Q37554425-381ACD7B-B70A-4B7B-840D-C991E574357EQ37626169-154778CF-0BB4-4F97-B049-09C5002E8EB6Q38193200-DBCC1D96-25BD-47E6-8EA5-82EA2F20DA76Q38351385-E60FE001-DD14-4E37-9365-C34D5C055144Q38367112-DFC0D833-3DC8-4313-A36A-798F1E64B9BFQ38380621-C8EF3733-44A1-4900-BCBC-FC5143E26AA3Q38420688-E1E2976D-789C-4C63-8C85-C05D913D395FQ38455786-E5507239-CDB5-4D44-835E-567A8DEB4878Q38671211-69370ADB-4910-406B-8E19-675FF5DE58C8Q38714060-06602AFF-8358-488B-8C88-131704FF2F4BQ38888350-0A40021F-C623-452F-B10B-5DF47AD6BE2DQ39025680-2BAD8236-3D95-444E-95DA-48E291F7EC56Q40258577-4B989F6E-69AB-4AB1-ACF7-5F9DC61E8DDAQ40991626-65B2D168-D5FE-4393-97B6-8C3CD9693625Q41582110-E8DDD4FD-CF60-4287-8E24-4BE8F6F08113Q41704262-8DE8A73F-C984-4AA0-8E07-BCE829E8D37EQ42351660-FEF23DD1-6D76-41F4-BCFD-1AF8C982314BQ45330127-26425676-0A75-4577-A25D-4158E02C30CA
P2860
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Basic concepts in physiologica ...... rug discovery and development.
@en
type
label
Basic concepts in physiologica ...... rug discovery and development.
@en
prefLabel
Basic concepts in physiologica ...... rug discovery and development.
@en
P2860
P356
P1476
Basic concepts in physiologica ...... rug discovery and development.
@en
P2093
K Rowland-Yeo
P2860
P356
10.1038/PSP.2013.41
P577
2013-08-14T00:00:00Z